Randomized trialMedical2026

A Pilot Investigation of Endocannabinoid System Markers and Lipopolysaccharide Responses to 10 Sessions of Hyperbaric Oxygen Therapy.

Wiącek J.; Pospieszna B.; Ciekot-Sołtysiak M.; Zieliński J.; Kusy K.; Podgórski T.; Karolkiewicz J. · Medical science monitor : international medical journal of experimental and clinical research · 2026

Research summary

**Background & Methods** This pilot randomized controlled trial examined whether 10 sessions of hyperbaric oxygen therapy (HBOT) modulated endocannabinoid system markers in 17 healthy, physically active men (9 HBOT, 8 controls). HBOT consisted of 60-minute sessions at 2.5 atmospheres absolute pressure with 100% oxygen, delivered 6 times weekly as three 20-minute oxygen periods separated by air breaks, with serum biomarkers measured before and after treatment using enzyme-linked immunosorbent assays. **Key Findings** • No significant between-group differences were observed for primary outcomes anandamide (AEA, p=0.597) or lipopolysaccharide (LPS, p=0.885), nor for secondary markers cannabinoid receptor type 2 (CB2R, p=1.000) or fatty acid amide hydrolase (FAAH, p=0.885) • No significant within-group changes occurred in the HBOT arm across any measured endocannabinoid or inflammatory biomarkers • Baseline AEA showed a positive correlation with baseline LPS levels (Spearman's rho=0.505, p=0.039), suggesting an association between endocannabinoid tone and lipopolysaccharide-induced inflammation **Dosage & Administration** 10 sessions of hyperbaric oxygen therapy at 2.5 atmospheres absolute pressure, 100% oxygen, 60 minutes per session (three 20-minute oxygen-breathing periods separated by two 5-minute air breaks), administered 6 times weekly. **Safety & Adverse Effects** Not reported. **Evidence Quality** This pilot study has significant limitations. The post-randomization, resource-limited sample of only 17 participants is severely underpowered for definitive conclusions. The control group was retroactively selected to match baseline BMI, introducing selection bias. The exploratory biomarker subanalysis design and multiple comparisons without correction increase Type I error risk. The authors acknowledge that negative findings do not exclude smaller, clinically meaningful effects, and the interesting baseline AEA-LPS association requires confirmation in adequately powered studies. The study provides preliminary data only (Level 3 evidence) and cannot establish whether HBOT meaningfully affects endocannabinoid system function or inflammatory responses in humans.

Summary generated by DeepWeed from the published abstract. See the original paper for full methods and results.

Journal
Medical science monitor : international medical journal of experimental and clinical research
Year
2026
Study type
Randomized trial
Read the original paper (DOI) ↗
Ask how this study fits the wider evidence — across 26,000+ papers.
Ask DeepWeed

More recent cannabis research

This page summarises published research for informational purposes only — it isn't medical advice. Always refer to the original publication for full methods, results and limitations.

← Back to home